Dynamics of Fibrosis in Chronic Idiopathic (Primary) Myelofibrosis During Therapy: A follow-up Study on 309 Patients
Authors:
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (6) , 949-953
Abstract
Controversial issues in chronic idiopathic myelofibrosis (IMF) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis. For this reason, a multicenter observational study was performed on 309 patients with IMF that had a long follow-up including 822 bone marrow biopsies at a median interval of 32 months. In addition to a control group (156 patients) with symptomatic treatment, monotherapy consisted of busulfan (30 patients), hydroxyurea (52 patients), interferon (26 patients) and various combinations (48 patients). Density and quality (reticulin/collagen) of fibers was determined by a semiquantitative scoring system. Independent of therapeutic regimens at the time of the last bone marrow biopsy 67% of the patients with grades 0-2 fibrosis revealed a progression, 42% stable state and 6% regression of myelofibrosis. Because of significant differences concerning frequencies of biopsies and endpoints of examinations, individual changes in the grades of fibrosis were evaluated with regard to treatment applied at standardized intervals of 20 months. According to this calculation no relevant differences in the dynamics of myelofibrosis (progression, stable state) was detectable in the control group compared to the other therapeutic modalities. The few patients with a regression of myelofibrosis usually presented with severe hypoplasia compatible with a myelo-ablative effect by aggressive chemotherapy. In conclusion, persuasive evidence has been produced that myelofibrosis in IMF is characterized by a stepwise progression and that this process is not significantly influenced by current treatment strategies.Keywords
This publication has 41 references indexed in Scilit:
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000
- Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groupsBritish Journal of Haematology, 1998
- Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosisBritish Journal of Haematology, 1997
- Idiopathic Primary Osteo-myelofibrosis: A Clinico-Pathological Study on 208 Patients with Special Emphasis on Evolution of Disease Features, Differentiation from Essential Thrombocythemia and Variables of Prognostic ImpactLeukemia & Lymphoma, 1996
- The Role of α-Interferon in Essential Thrombocythaemia, Polycythaemia Vera and Myelofibrosis with Myeloid Metaplasia (MMM): A Concise UpdateLeukemia & Lymphoma, 1995
- Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survivalAnnals of Hematology, 1994
- A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosisEuropean Journal of Haematology, 1991
- Induction and maintenance alpha‐interferon therapy in myelofibrosis with myeloid metaplasiaEuropean Journal of Haematology, 1990
- Chronic Myeloproliferative Disorders in Bone Marrow BiopsiesPathology - Research and Practice, 1990
- Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasiaEuropean Journal of Haematology, 1987